The Use of APC/C Antagonists to Promote Mitotic Catastrophe in Cancer Cells.
| Autor: | Mayah A; Oxford Target Therapeutics (OTT), Bioinnovation Hub, Oxford, UK., Arenas RB; Departamento de Química Bio-orgánica, IQOG, Madrid, Spain., Bastida A; Departamento de Química Bio-orgánica, IQOG, Madrid, Spain. agatha.bastida@csic.es., Bolanos-Garcia VM; Oxford Target Therapeutics (OTT), Bioinnovation Hub, Oxford, UK. vbolanos-garcia@brookes.ac.uk.; Faculty of Health and Life Sciences, Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK. vbolanos-garcia@brookes.ac.uk. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2025; Vol. 2874, pp. 207-213. |
| DOI: | 10.1007/978-1-0716-4236-8_17 |
| Abstrakt: | The multiprotein subunit E3 ubiquitin ligase Anaphase-Promoting Complex/Cyclosome (APC/C) plays a key role in the control of mitosis progression. APC/C is the ultimate effector of the Spindle Assembly Checkpoint (SAC), the signaling system of higher organisms including the human that monitors the proper attachment of chromosomes to microtubules during cell division. Defects in this process result in genome instability, aneuploidy, premature aging, and cancer. APC/C roles in the SAC require its activation by the protein Cdc20. Interfering with APC/C activation by Cdc20 impairs APC/C substrate recognition, resulting in a delayed mitotic exit and eventually inducing cell death. This may be advantageous for the treatment of cancer and malignancies associated with SAC dysregulation. Here we describe a protocol to interfere with mitotic exit through the use of commercially available (Apcin, proTAME) as well as innovative small molecules we have developed that function as antagonists of APC/C activation by Cdc20. We show that the use of these molecules alone and in combination is effective to promote mitotic catastrophe and suppress cell expansion in 2D and 3D (spheroids) cancer cells of different tissue origin, including breast, cervical, and ovarian cancer. (© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|